What the Study Found (In Plain English)
Published in The journal of pathology. Clinical research (2022), this phase iii randomized trial evaluating 70 human participants investigated: Histopathological growth patterns (HGPs) are a reliable, reproducible, and strong prognostic biomarker that can be assessed on haematoxylin and eosin-stained sections of resected colorectal liver metastases (CRLM). Key clinical takeaway: In the original cohort, the average presence of desmoplastic HGP was 43% for chemo-naïve versus 67% for preoperatively treated patients (p 0.11). Preoperative chemotherapy induces histopathological changes that alter the HGP of CRLM.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (The journal of pathology. Clinical research, 2022-01-15; N = 70; Rigor 82/100): In the original cohort, the average presence of desmoplastic HGP was 43% for chemo-naïve versus 67% for preoperatively treated patients (p 0.11). Preoperative chemotherapy induces histopathological changes that alter the HGP of CRLM.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.